Aspire Biopharma Holdings (ASBP) Other Accumulated Expenses (2022 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Other Accumulated Expenses of $353679.0 for Q1 2026, little changed year-over-year from $353679.0 in Q1 2025, and little changed quarter-over-quarter from $353679.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Other Accumulated Expenses (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Other Accumulated Expenses for 5 consecutive years, with $353679.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses changed 0.0% year-over-year to $353679.0; the TTM figure through Mar 2026 stood at $353679.0 (changed 0.0% YoY), while the FY2025 annual figure was $353679.0, up 218.56% from the prior year.
- Other Accumulated Expenses held at $353679.0 in Q1 2026 per ASBP's latest filing, from $353679.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $353679.0 in Q1 2025 and bottomed at $111026.0 in Q4 2024.
- Historically, Other Accumulated Expenses has averaged $266962.8 across 5 years, with a median of $283939.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses tumbled 53.53% — and 2025, when it soared 218.56%.
- Aspire Biopharma Holdings' Other Accumulated Expenses stood at $122689.0 in 2022, then jumped by 94.75% to $238939.0 in 2023, then sank by 53.53% to $111026.0 in 2024, then jumped by 218.56% to $353679.0 in 2025, then changed by 0.0% to $353679.0 in 2026.
- Business Quant data shows ASBP's Other Accumulated Expenses at $353679.0 in Q1 2026, $353679.0 in Q4 2025, and $353679.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 353,679.00 |
| Dec 31, 2025 | 353,679.00 |
| Sep 30, 2025 | 353,679.00 |
| Jun 30, 2025 | 353,679.00 |
| Mar 31, 2025 | 353,679.00 |
| Dec 31, 2024 | 111,026.00 |
| Jun 30, 2024 | 298,939.00 |
| Mar 31, 2024 | 268,939.00 |
| Dec 31, 2023 | 238,939.00 |
| Sep 30, 2023 | 211,937.00 |
| Jun 30, 2023 | 182,689.00 |
| Dec 31, 2022 | 122,689.00 |